Clinical
A single MOTYS™ injection provides unparalleled, durable improvements in pain and function.
Large clinical database (n<350) provides clear
direction for successful Phase 3 clinical study execution
IND Phase 1 safety study
(n=20; 12-month follow up)
- No safety findings, no immunological reactions
- Potent and durable effect on symptom relief reported up to 12 months
Open-label RWE study
(n=140; 12-month follow up)
- After 12 months, 70% still patients experience benefits from a single injection of MOTYS™
Phase 2b RCT
(n=215; 6-month follow up, placebo controlled)
- 70% improvement on pain and mobility scores at 6 months
- Informed the design of a risk mitigated Phase 3 study
Contact Us
Our team can help to answer any of your questions.
Get in touch to learn more about Doron Therapeutics.